Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
SALMETEROL REDUCES DYSPNEA AND IMPROVES LUNG-FUNCTION IN PATIENTS WITH COPD
Autore:
RAMIREZVENEGAS A; WARD J; LENTINE T; MAHLER DA;
Indirizzi:
DARTMOUTH HITCHCOCK MED CTR,SECT PULM & CRIT CARE MED 3D,1 MED CTR DRLEBANON NH 03756 DARTMOUTH COLL SCH MED,DEPT MED LEBANON NH 00000
Titolo Testata:
Chest
fascicolo: 2, volume: 112, anno: 1997,
pagine: 336 - 340
SICI:
0012-3692(1997)112:2<336:SRDAIL>2.0.ZU;2-H
Fonte:
ISI
Lingua:
ENG
Soggetto:
OBSTRUCTIVE PULMONARY-DISEASE; AIR-FLOW LIMITATION; ASTHMA; BREATHLESSNESS; FORMOTEROL; MANAGEMENT; ALBUTEROL;
Keywords:
CHRONIC OBSTRUCTIVE PULMONARY DISEASE; DYSPNEA; REDUCED HYPERINFLATION; SALMETEROL;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Science Citation Index Expanded
Citazioni:
24
Recensione:
Indirizzi per estratti:
Citazione:
A. Ramirezvenegas et al., "SALMETEROL REDUCES DYSPNEA AND IMPROVES LUNG-FUNCTION IN PATIENTS WITH COPD", Chest, 112(2), 1997, pp. 336-340

Abstract

Study objective: To investigate the short-term effects of inhaled salmeterol on the perception of dyspnea and lung function in patients with COPD. Design: Double-blind, crossover, randomized trial comparing inhaled salmeterol and inhaled placebo over 4 h. Setting: Pulmonary function laboratory at university medical center. Patients: Sixteen patients with symptomatic COPD and at least 200-mL increase in FEV1 after inhalation of two puffs (180 mu g) of albuterol. Interventions: Visit 1 was used for familiarization. At visits 2 and 3 (2 to 3 days apart), patients inhaled either two puffs of salmeterol (42 mu g) or placebo. Measurements and results: Lung function and dyspnea were measured at 0.5, 2, and 4 h after inhalation of the study medication. Dyspnea was measured by the -5 to +5 category scale at rest and by the 0 to 10 category-ratio scale while breathing through inspiratory resistances of 5, 15, and 30 cm H2O/L/s. Age was 66+/-8 years (mean+/-SD). FEV1 was 0.97/-0.331 (51+/-13% predicted). There were significantly higher values for FEV1 and FVC (at all time periods) and lower values for functionalresidual capacity (at all time periods) and residual volume (at 4 h) with salmeterol than with placebo. There were significantly lower dyspnea ratings on the -5 to +5 category scale (p=0.03 at 2 h and p=0.02 at 4 h) and for the mean dyspnea scores during resistive breathing withsalmeterol compared with placebo (p=0.002). Conclusions: Inhaled salmeterol reduced dyspnea, increased airflow, and reduced hyperinflation over 4 h in patients with symptomatic COPD.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 09/08/20 alle ore 23:33:24